Company news

Allarity Therapeutics, Inc. news in 2025

Allarity Therapeutics, Inc.'s news releases, calls and decks from 2025, newest first.

View company

Allarity Therapeutics Issues 2025 End of Year CEO Letter to Shareholders

December 31, 2025

Allarity Therapeutics Provides Third Quarter 2025 Financial Results and Provides Business Updates

November 14, 2025

Allarity Therapeutics Presents New Phase 2 Clinical Data for Stenoparib/2X-121 Showing Landmark Median Overall Survival Has Now Surpassed 25 Months

September 22, 2025

Allarity Therapeutics CEO to Present at Biomarkers & Precision Medicine 2025

September 17, 2025

Allarity Therapeutics Granted FDA Fast Track Designation for Stenoparib for the Treatment of Advanced Ovarian Cancer

August 26, 2025

Allarity Therapeutics Provides Second Quarter 2025 Update, Highlighting Clinical Progress, IP Expansion, and New Partnerships

August 15, 2025

Corporate Presentation 2025 Q2

July 24, 2025

Allarity Therapeutics Announces New Licensing and Laboratory Services Agreement to Expand DRP® Platform Utilization

July 15, 2025

Allarity Therapeutics Announces Appointment of Jeff Ervin as Chief Financial Officer

July 7, 2025

Allarity Therapeutics Receives Australian Patent Acceptance Notice for Stenoparib DRP® Companion Diagnostic

June 30, 2025

Allarity Therapeutics Announces Dosing of Second Patient in New Phase 2 Trial of Stenoparib in Advanced Ovarian Cancer

June 27, 2025

Allarity Therapeutics Announces Changes to Board of Directors

June 11, 2025

Allarity Therapeutics Announces Research Collaboration with Indiana Biosciences Research Institute to Further Advance Understanding of Stenoparib’s Unique, Dual Therapeutic Mechanism of Action

June 4, 2025

Allarity Therapeutics Announces First Patient Enrolled in New Phase 2 Clinical Trial Protocol of Stenoparib in Advanced Ovarian Cancer

June 2, 2025

Allarity Therapeutics Announces Participation in Pharma Partnering Summit US

May 12, 2025

Allarity Therapeutics Provides First Quarter 2025 Update, Highlighting Continued Stenoparib Benefit and Upcoming Trial Enrollment

May 9, 2025

Allarity Therapeutics Presents Novel Drug Response Predictor—DRP®—for Daratumumab in Multiple Myeloma at AACR 2025

April 24, 2025

Allarity Therapeutics Reports Full Year 2024 Financial Results and Provides a Business Update

March 31, 2025

Allarity Therapeutics Launches Comprehensive Effort to Combat Potential Illegal Naked Short Selling of Its Shares

March 24, 2025

Allarity Therapeutics Announces Presentation of Phase 2 Clinical Data from Ongoing Trial in Advanced Ovarian Cancer Patients at the 2025 Annual Meeting for the Society of Gynecologic Oncology

March 17, 2025

Allarity Therapeutics Announces Final Settlement with the U.S. Securities and Exchange Commission

March 13, 2025

Allarity Therapeutics Announces Phase 2 Trial of Stenoparib in Combination with Temozolomide for Recurrent Small Cell Lung Cancer Fully Funded by the US Veterans Administration

March 6, 2025

Allarity Therapeutics Announces Board Authorization of $5 Million Share Repurchase Program

March 3, 2025

Allarity Therapeutics Announces Dismissal of Securities Class Action Lawsuit

February 26, 2025

Allarity Therapeutics to Begin Enrollment for New Phase 2 Protocol to Advance Stenoparib Toward FDA Approval in Advanced Ovarian Cancer Patients

February 24, 2025

Allarity Therapeutics Announces Expansion of Phase 2 Clinical Trial to Accelerate Development of Stenoparib in Advanced Ovarian Cancer

February 5, 2025

Allarity Therapeutics Announces Filing of Form 8-K Regarding Settlement Agreement in Principle with SEC

January 29, 2025

Decks in 2025